Skip to main content
. Author manuscript; available in PMC: 2014 Jul 14.
Published in final edited form as: Toxicol Pathol. 2012 Nov 28;41(5):744–760. doi: 10.1177/0192623312464308

Figure 4.

Figure 4

Immunolabeling for MSA as a measure of stellate cell myofibroblastic transdifferentiation. Representative picture of a control liver (4A) and liver with hepatic fibrosis (4B). MSA immunohistochemistry, hematoxylin counterstain. Bar = 50 μm 40X.